miR‑140‑3p enhances cisplatin sensitivity and attenuates stem cell‑like properties through repressing Wnt/β‑catenin signaling in lung adenocarcinoma cells

Wu,Shuoming; Wang,Haoran; Pan,Yinpeng; Yang,Xiangbao; Wu,Duoguang

doi:10.3892/etm.2020.8847

miR‑140‑3p enhances cisplatin sensitivity and attenuates stem cell‑like properties through repressing Wnt/β‑catenin signaling in lung adenocarcinoma cells

Authors:
- Shuoming Wu
- Haoran Wang
- Yinpeng Pan
- Xiangbao Yang
- Duoguang Wu
View Affiliations

Affiliations: Department of Thoracic Surgery, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China, Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China, Department of Thoracic Surgery, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: June 5, 2020 https://doi.org/10.3892/etm.2020.8847
Pages: 1664-1674
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is the most predominant subtype of non‑small cell lung cancer (NSCLC) that is experiencing the fastest growth rate in incidence. Chemoresistance and the presence of cancer stem cells are considered to be the main obstacles preventing the successful treatment of patients with NSCLC, the molecular mechanism of which remains poorly understood. The present study aimed to investigate the effects of microRNA (miR)‑140‑3p on cisplatin sensitivity and stem cell‑like properties of LUAD cells. Analysis of publicly available data demonstrated that miR‑140‑3p expression was downregulated in LUAD, and positively associated with the overall survival rate of patients. In addition, transfection with the miR‑140‑3p mimic reduced LUAD cell viability and induced apoptosis following treatment with cisplatin whilst decreasing stem cell‑like properties. miR‑140‑3p overexpression was also found to attenuate cisplatin resistance and reduce stem cell‑like properties in LUAD cells by suppressing Wnt/β‑catenin signaling, all of which were reversed by the overexpression of β‑catenin. Taken together, results of the present study suggest miR‑140‑3p to be an effective therapeutic strategy for patients with LUAD.

View Figures

View References

1	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
5	Han L, Xu G, Xu C, Liu B and Liu D: Potential prognostic biomarkers identified by DNA methylation profiling analysis for patients with lung adenocarcinoma. Oncol Lett. 15:3552–3557. 2018.PubMed/NCBI View Article : Google Scholar
6	Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry D: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 44:42–50. 2016.PubMed/NCBI View Article : Google Scholar
7	Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10. 2011.PubMed/NCBI View Article : Google Scholar
8	Zarogoulidis P, Petanidis S, Kioseoglou E, Domvri K, Anestakis D and Zarogoulidis K: MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and survivin in lung cancer cells. Cell Signal. 27:1576–1588. 2015.PubMed/NCBI View Article : Google Scholar
9	Tian H, Liu S, Zhang J, Zhang S, Cheng L, Li C, Zhang X, Dail L, Fan P, Dai L, et al: Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting survivin. J Biomed Nanotechnol. 8:633–641. 2012.PubMed/NCBI View Article : Google Scholar
10	Zhang Y, Yuan Y, Li Y, Zhang P, Chen P and Sun S: An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma. Epigenetics. 14:949–960. 2019.PubMed/NCBI View Article : Google Scholar
11	Li J, Wang Y, Song Y, Fu Z and Yu W: MiR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 13(193)2014.PubMed/NCBI View Article : Google Scholar
12	Zhan J, Wang P, Li S, Song J, He H, Wang Y, Liu Z, Wang F, Bai H, Fang W, et al: HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. Theranostics. 9:2084–2099. 2019.PubMed/NCBI View Article : Google Scholar
13	Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.PubMed/NCBI View Article : Google Scholar
14	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008.PubMed/NCBI View Article : Google Scholar
15	Lathia J, Liu H and Matei D: The clinical impact of cancer stem cells. Oncologist. 17(0517)2019.PubMed/NCBI View Article : Google Scholar
16	Bora-Singhal N, Mohankumar D, Saha B, Colin CM, Lee JY, Martin MW, Zheng X, Coppola D and Chellappan S: Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2. Sci Rep. 10(4722)2020.PubMed/NCBI View Article : Google Scholar
17	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008.PubMed/NCBI View Article : Google Scholar
18	Lu CH, Yeh DW, Lai CY, Liu YL, Huang LR, Lee AY, Jin SC and Chuang TH: USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation. Oncogene. 37:6327–6340. 2018.PubMed/NCBI View Article : Google Scholar
19	Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW: Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70:10433–10444. 2010.PubMed/NCBI View Article : Google Scholar
20	Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol. 45:872–877. 2005.PubMed/NCBI View Article : Google Scholar
21	Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP: Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol. 12:445–464. 2015.PubMed/NCBI View Article : Google Scholar
22	Chatterjee S and Sil PC: Targeting the crosstalks of Wnt pathway with hedgehog and notch for cancer therapy. Pharmacol Res. 142:251–261. 2019.PubMed/NCBI View Article : Google Scholar
23	Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al: Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 74:7573–7582. 2014.PubMed/NCBI View Article : Google Scholar
24	Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 29:1661–1671. 2011.PubMed/NCBI View Article : Google Scholar
25	Wang X, Meng Q, Qiao W, Ma R, Ju W, Hu J, Lu H, Cui J, Jin Z, Zhao Y and Wang Y: MiR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Res Ther. 9(327)2018.PubMed/NCBI View Article : Google Scholar
26	Liu T, Wu X, Chen T, Luo Z and Hu X: Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/β-catenin signaling. Clin Cancer Res. 24:1748–1760. 2018.PubMed/NCBI View Article : Google Scholar
27	Sun T, Song Y, Yu H and Luo X: Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis. Cancer Biol Ther. 20:760–773. 2019.PubMed/NCBI View Article : Google Scholar
28	Zhang QY, Men CJ and Ding XW: Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN. J Cell Biochem. 120:14885–14898. 2019.PubMed/NCBI View Article : Google Scholar
29	Zhou Y, Wang B, Wang Y, Chen G, Lian Q and Wang H: MiR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28. Oncol Lett. 17:3835–3841. 2019.PubMed/NCBI View Article : Google Scholar
30	Li J, Zhao J, Wang H, Li X, Liu A, Qin Q and Li B: MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Onco Targets Ther. 11:5885–5894. 2018.PubMed/NCBI View Article : Google Scholar
31	Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 17:6802–6811. 2011.PubMed/NCBI View Article : Google Scholar
32	Huang H, Wang Y, Li Q, Fei X, Ma H and Hu R: MiR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9. Cancer Lett. 446:81–89. 2019.PubMed/NCBI View Article : Google Scholar
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
34	Cao S, Wang Z, Gao X, He W, Cai Y, Chen H and Xu R: FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res. 37(220)2018.PubMed/NCBI View Article : Google Scholar
35	Cui Y, Ma W, Lei F, Li Q, Su Y, Lin X, Lin C, Zhang X, Ye L, Wu S, et al: Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling. J Pathol. 239:297–308. 2016.PubMed/NCBI View Article : Google Scholar
36	MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ and Barr MP: Lung cancer stem cells: The root of resistance. Cancer Lett. 372:147–156. 2016.PubMed/NCBI View Article : Google Scholar
37	Jiang N, Zou C, Zhu Y, Luo Y, Chen L, Lei Y, Tang K, Sun Y, Zhang W, Li S, et al: HIF-1a-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and notch signaling. Theranostics. 10:2553–2570. 2020.PubMed/NCBI View Article : Google Scholar
38	Li T, Ding ZL, Zheng YL and Wang W: MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting apaf-1 associated with the suppression of apoptosis. Biomed Pharmacother. 96:153–164. 2017.PubMed/NCBI View Article : Google Scholar
39	Ma Z, Cai H, Zhang Y, Chang L and Cui Y: MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1. Biochem Biophys Res Commun. 490:309–316. 2017.PubMed/NCBI View Article : Google Scholar
40	Zhang Y, Du H, Li Y, Yuan Y, Chen B and Sun S: Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma. Cancer Sci. 111:637–646. 2020.PubMed/NCBI View Article : Google Scholar
41	Chen MJ, Wu DW, Wang YC, Chen CY and Lee H: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via beta-catenin-mediated stemness. Sci Rep. 6(34933)2016.
42	MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ and Barr MP: BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 428:117–126. 2018.PubMed/NCBI View Article : Google Scholar
43	Lathia JD and Liu H: Overview of cancer stem cells and stemness for community oncologists. Targeted Oncol. 12:387–399. 2017.PubMed/NCBI View Article : Google Scholar
44	Najafi M, Farhood B and Mortezaee K: Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 234:8381–8395. 2019.PubMed/NCBI View Article : Google Scholar
45	Fu X, Wu S, Li B, Xu Y and Liu J: Functions of p53 in pluripotent stem cells. Protein Cell. 11:71–78. 2020.PubMed/NCBI View Article : Google Scholar
46	Cao X, Hou J, An Q, Assaraf YG and Wang X: Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 49(100671)2019.PubMed/NCBI View Article : Google Scholar